Although visual processing impairments are common in schizophrenia, it is not clear to what extent these originate in the eye vs. the brain. This review highlights potential contributions, from the retina and other structures of the eye, to visual processing impairments in schizophrenia and high-risk states. A second goal is to evaluate the status of retinal abnormalities as biomarkers for schizophrenia. The review was motivated by known retinal changes in other disorders (e.g., Parkinson's disease, multiple sclerosis), and their relationships to perceptual and cognitive impairments, and disease progression therein. The evidence reviewed suggests two major conclusions. One is that there are multiple structural and functional disturbances of the eye in schizophrenia, all of which could be factors in the visual disturbances of patients. These include retinal venule widening, retinal nerve fiber layer thinning, dopaminergic abnormalities, abnormal ouput of retinal cells as measured by electroretinography (ERG), maculopathies and retinopathies, cataracts, poor acuity, and strabismus. Some of these are likely to be illness-related, whereas others may be due to medication or comorbid conditions. The second conclusion is that certain retinal findings can serve as biomarkers of neural pathology, and disease progression, in schizophrenia. The strongest evidence for this to date involves findings of widened retinal venules, thinning of the retinal nerve fiber layer, and abnormal ERG amplitudes. These data suggest that a greater understanding of the contribution of retinal and other ocular pathology to the visual and cognitive disturbances of schizophrenia is warranted, and that retinal changes have untapped clinical utility. Visual processing impairments are well established in schizophrenia, including abnormalities in contrast sensitivity (Kelemen et al., 2013; Kiss et al., 2010) ; various excitatory and inhibitory functions (Kaplan and Lubow, 2011; Keri et al., 2005a; Robol et al., 2013) including those involved in masking and surround suppression ; and form and motion processing (Chen, 2011; Green et al., 2011; Javitt, 2009; Silverstein and Keane, 2011) . There has been little work on color processing to date (Shuwairi et al., 2002) , but clinical reports indicate frequent descriptions of increased intensity, or alterations in color perception (Chapman, 1966; VollmerLarsen et al., 2007). One study reported a 62% incidence of visual distortions in schizophrenia, with brightness, contrast, and motion increases being the most commonly reported (Phillipson and Harris, 1985) . Visual distortions also had the highest predictive validity, among all basic symptoms, for conversion to a psychotic disorder (Klosterkotter et al., 2001) , and visual distortions in help-seeking adolescents are associated with suicidal ideation, even after controlling for age, gender, depression, thought disorder, paranoia, and auditory distortions (Grano et al., 2015) . Finally, visual impairments contribute substantially to poorer real-world functioning in people with schizophrenia (Green et al., 2012; Rassovsky et al., 2011) .
In spite of this growing body of evidence, an unanswered question is the extent to which the problems observed in recent laboratory or clinical reports are due to changes in the eye vs. in the brain. It has already been shown that abnormalities (i.e., hypo-or hyper-activation) exist in occipital (Butler et al., 2013; , temporal (Silverstein et al., 2010a) , parietal (Dima et al., 2009) , and prefrontal (Dima et al., 2009; Silverstein et al., , 2010b regions during visual processing tasks in schizophrenia, depending on the nature of the task requirements. These findings are thought to reflect both inefficient stimulus-driven (i.e., bottom-up) processing, as well as deficient topdown guidance or modulation of the feedforward sweep of information based on prior knowledge, expectations, and task strategies (Dima et al., 2009 (Dima et al., , 2010 (Dima et al., , 2011 Keane et al., 2013; Silverstein and Keane, 2009 ). However, degraded input to the visual system could contribute to both sets of findings, by adding noise to (or lowering the resolution of) sensory information, which would disrupt stimulus-driven processing, and by making it less likely that appropriate stimulus templates or memory representations would be activated to modulate processing. It is the purpose of this review to: 1) highlight potential mechanisms by which schizophrenia, or its treatment, can disrupt retinal function and lead to some of the common laboratory findings or visual distortions reported by patients; and 2) describe other types of ocular dysfunction that may contribute to these visual impairments. The extent to which these retinal and other ocular changes can serve as biomarkers for schizophrenia or psychosis will also be highlighted.
Retinal cellular and vascular changes in schizophrenia and high-risk states
The retina is an active information processor, in which, among other things, early forms of transformations traditionally thought to occur only in visual cortex, take place. For example, in response to moving stimuli, cone photoreceptors produce motion blur, which has been shown to enhance information about orientation and direction of movement, shape contour orientation and completion, changes in texture between stimulus regions, spatial frequency, and depth (van Tonder, 2010) . Motion blur can also affect perception of complex stimuli such as facial emotions. Importantly, much input to cone photoreceptors (the photoreceptor type involved in color vision) is dopaminergic, and, as reviewed below, retinal dopamine (DA) abnormalities could contribute to several forms of visual impairments in schizophrenia. An implication of this is that anything that affects retinal function may result in intensified, degraded or noisy input to higher levels of processing in LGN and visual cortex, depending on the nature of the abnormality.
The retina develops from the same tissue (neuroectoderm) as the brain, and is the only part of the central nervous system that can be seen with the naked eye in its natural state in living organisms. Given that retinal changes may parallel, or mirror the integrity of brain structure and function (Chu et al., 2012; Kemenyova et al., 2014; Lee et al., 2013; Tian et al., 2011) , it has been suggested that retinal changes can serve as a marker of progressive brain tissue loss. Given this, the welldocumented structural and functional brain changes in schizophrenia, and the obvious implications of altered retinal function for changes in visual processing, what is the evidence for retinal abnormalities in schizophrenia?
Data from the Dunedin longitudinal study indicated that, at age 38, individuals with schizophrenia had wider retinal venules than cohort members who did not have schizophrenia, suggesting a history of chronic insufficient brain oxygen supply . This finding was not secondary to other health issues. Moreover, wider retinal venules were associated with extent of psychotic symptoms in adulthood, and in childhood. The association between wider retinal venule width and psychosis (assessed 6 years after the eye exam) was recently replicated in two Australian twin studies (Meier et al., 2015) . Moreover, retinal venule width in unaffected twins of a psychotic sibling was characterized by values intermediate between controls and psychotic siblings. Arteriole width was unaffected by presence of psychosis in twins with psychosis or their unaffected siblings. These data suggested that retinal venule widening may be a proxy marker of familial risk for psychosis. Other evidence indicates that retinal venule width is significantly correlated with childhood IQ and with neuropsychological functioning at midlife, in the general population . A similar recent finding is that, in the general population, color vision impairments [implying DA dysregulation in cone photoreceptors (see below)] predict difficulties with cognitive control (Colzato et al., 2014 ) -a function thought to involve dopaminergic projections to the prefrontal cortex (van Schouwenburg et al., 2010) , and that is characteristically impaired in schizophrenia (Lesh et al., 2011) . These data suggest that basic aspects of retinal structure and function may indicate increased risk for schizophrenia, and be impaired in the disorder, via reflecting reduced vascular and brain health.
Other evidence for structural retinal changes in schizophrenia comes from studies of optical coherence tomography (OCT). OCT is a recently developed, rapid, non-invasive imaging technique that can reveal retinal structure in vivo with axial resolutions of 5 microns or less. It has recently proven useful for identifying thinning of certain retinal layers in several neurological conditions such as multiple sclerosis (MS) (Khanifar et al., 2010; Martinez-Lapiscina et al., 2014 ), Parkinson's disease (Satue et al., 2013 (Satue et al., , 2014 Tian et al., 2011) , and Alzheimer's disease (Moschos et al., 2012) , in addition to focal eye diseases (Leung et al., 2010) . Retinal nerve fiber layer (RNFL) thinning -reflecting loss of ganglion cell axons that leave the retina as the optic nerve and synapse onto the lateral geniculate nucleus -as revealed by OCT, is thought to be a good model of brain neurodegeneration, since retinal cells are unmyelinated, and so any thinning directly reflects cell loss (Lee et al., 2013) . Consistent with this, progressive RNFL thinning parallels disease progression in Parkinson's disease (Tian et al., 2011) , where level of thinning correlates significantly with extent of visual hallucinations (Lee et al., 2014) and functional disability (Satue et al., 2014) . In MS, RNFL thinning is associated with duration of illness, gray matter loss, poorer executive functioning, poorer overall cognitive functioning, illness progression, and relapse (Martinez-Lapiscina et al., 2014; Ratchford et al., 2013; Saidha et al., 2013; Sedighi et al., 2014; Toledo et al., 2008) . Interestingly, even in healthy subjects, OCT indices correlate with intracranial volume . OCT studies of schizophrenia have focused on RNFL thinning and reductions in macular volume (MV) (reflecting integrity of the fovea and surrounding tissue). While an initial small study (n=10 patients) reported RNFL thinning (Ascaso et al., 2010) , this was not replicated in a subsequent study (Chu et al., 2012) , although in the latter, reduced MV was related to increased positive symptoms. However, this study used an earlier generation (time domain) OCT device characterized by an~10 micron axial resolution generating 400 scans per second. More recent studies, using spectral-domain OCT with resolution of~5 microns and over 25,000 scans per second, have observed both RNFL and MV thinning (Lee et al., 2013) , or RNFL thinning only (Cabezon et al., 2012) , in schizophrenia (see Figs. 1 and 2). As with retinal venule widening, the functional significance of these findings is not yet clear, although one study found that RNFL thinning was related to illness chronicity in schizophrenia (Lee et al., 2013) . Studies investigating the relationship between retinal degeneration and visual processing are just beginning to be carried out with schizophrenia patients. However, it is thought that problems in visual processing (including in contrast sensitivity, color perception, and reading) in Parkinson's disease may be due to retinal cell loss (Djamgoz et al., 1997; Harnois and Di Paolo, 1990; Hutton and Morris, 2001; Rodnitzky, 1998) , and similar problems have been observed in schizophrenia (Butler et al., 2005; Cadenhead et al., 2013; Kelemen et al., 2013; Revheim et al., 2006b Revheim et al., , 2014 ) (see below). In addition, as described in the next section, ganglion cell loss (which may be the primary cause of RNFL thinning) may be a marker of other cellular processes that have been linked to specific visual impairments. An additional consideration for studies of schizophrenia is that diabetic retinal changes (maculopathy) detectable by OCT (Sikorski et al., 2013) could contribute to visual processing disturbances, and so must be ruled out in both eyes of patients.
Dopamine and retinal function
DA is a major neurotransmitter in the vertebrate retina, and its cellular localization and functions are similar in organisms as diverse as fish and primates (Djamgoz et al., 1997; Masson et al., 1993) . In the retina, DA originates in one class of amacrine cells (ACs) and in interplexiform cells. It is transmitted via standard synaptic transmission, as well as by volume transmission, where it can diffuse up to 3 mm through retinal tissue to potentially influence every type of retinal neuron, as all have receptors for DA (Yazulla and Studholme, 1995) . One important function of DA in the retina is to weaken the gap junctions that couple horizontal cells (Piccolino et al., 1984; Teranishi et al., 1983) . Because horizontal cells (HCs) pool the activity of photoreceptor cells across space, this DA-related uncoupling leads to significant reduction of the normally large HC receptive fields (Xin and Bloomfield, 2000) , and to increased sensitivity to local (relative to contextual) stimulation (Brandies and Yehuda, 2008) . A second effect of the uncoupling of HCs is reduced interaction between neurons signaling light and dark portions of space, leading to enhanced center responses (and reduced effects of surround responses) (Hedden and Dowling, 1978) .
The DA receptor types found in the retina are the same as those found in the brain (e.g., D 1 -D 5 ), and can be roughly divided into D 1 and D 2 types (Brandies and Yehuda, 2008) . Endogenous DA inhibits suprathreshold rod-mediated ON and OFF responses. However, with cones, DA increases excitation for ON responses, and increases inhibition for OFF responses in most cases (Popova and Kupenova, 2013) . It is thought that D 2 receptors are primarily involved in generating ON responses, whereas D 1 receptors are mainly responsible for OFF responses (Popova and Kupenova, 2013) . As a result of these asymmetries, excess DA at D 2 receptors can lead to hyper-intense color perception (as seen, for example, in early schizophrenia, see below), whereas reduced DA can lead to reductions in color perception (as seen, for example, in Parkinson's disease, see below).
Taken together, these data suggest that the excesses and reductions in DA activity repeatedly demonstrated in the brain in schizophrenia are likely to also occur in the retina, where they may play a significant role in visual processing disturbances. In the following two subsections, each of these scenarios, and their implications for understanding results of visual experiments in schizophrenia, is discussed.
Effects of reduced retinal DA on vision
Through studies of Parkinson's disease patients (including postmortem studies), along with animal and human studies of druginduced Parkinsonian symptoms (Bodis-Wollner and Tagliati, 1993; Bulens et al., 1989) , it is known that retinal DA is reduced in this condition (Tian et al., 2011) . Reduced retinal DA leads to excessively strong coupling of HCs and ACs, leading to increased inhibition, and subsequently to reduced contrast sensitivity and poorer color vision and visual acuity (Djamgoz et al., 1997) . Monkeys administrated MPTP or intraocular 6-OHDA (both of which destroy retinal DA neurons and reduce levels of retinal DA) show reduced processing of mid-range spatial frequencies (e.g., 2.5-3.5 cycles/degree) (Bodis-Wollner and Tagliati, 1993) , and these changes were temporarily reversed by L-DOPA administration (Bodis-Wollner, 1990 ). Humans with drug-induced Parkinsonism have demonstrated a general reduction in contrast sensitivity across all spatial frequencies (Bulens et al., 1989) , and the contrast sensitivity impairments in patients with Parkinson's Disease can be reversed (with less strong effects at high spatial frequencies) after L-DOPA administration (Bulens et al., 1987) . In addition, elderly subjects from the general population, who typically show poor low spatial frequency (LSF) processing, demonstrated improved processing across the full range of spatial frequencies after 3 months of treatment with the D 2 agonist piribedil (Corbe et al., 1992) . Moreover, in children and/or adults with amblyopia, a single dose of L-DOPA (but not placebo) significantly increased contrast sensitivity (Gottlob and StanglerZuschrott, 1990 ) and visual acuity (Leguire et al., 1992) , and effects on acuity were 3 times stronger after a week of L-DOPA (Gottlob et al., 1992) . Of note, these effects were obtained regardless of whether contrast was measured at, or above, detection threshold (Brandies and Yehuda, 2008) . Finally, in healthy rats and humans, haloperidol (Haldol), including a single dose, delayed visual evoked potentials (VEPs) (reviewed in (Brandies and Yehuda, 2008) ). These data are relevant to schizophrenia, because people with this condition typically take DA receptor antagonists, and have also demonstrated longer latency VEPs (Malyszczak et al., 2003) , and problems in visual acuity (Viertio Central colorized panel is a topographic map overlay (50% transparency) showing thickness (in μm) from the inner limiting membrane (ILM, which covers the retinal nerve fiber layer; see Fig. 2 ) to the retinal pigment epithelium (RPE, which is beneath the photoreceptor layer). Thickness scale is depicted by the legend on right side of figure. Right panel: average thickness values of the segments are colorized relative to age-matched control subjects. Regions in yellow denote values observed in less than 5% of age-matched subjects; regions in pink-red denote values observed in less than 1% of age-matched subjects. This patient demonstrates borderline significant or significant thinning in more than half of the macular subregions in this eye. et al., 2007), contrast sensitivity (Kelemen et al., 2013; Kiss et al., 2010; Slaghuis, 1998) , and LSF processing (Martinez et al., 2008 (Martinez et al., , 2012 , although the latter impairment is not always found (Keane et al., 2014a; Laprevote et al., 2010 Laprevote et al., , 2013 , and it may not be specific to low spatial frequencies (Skottun and Skoyles, 2007) .
The similarities between schizophrenia and Parkinson's disease discussed above raise the question: are the findings in schizophrenia due to disease-related retinal DA reductions, or to receptor blockade secondary to antipsychotic medication? Data on this issue suggest that antipsychotic medication can have negative effects on visual function. For example, while antipsychotic medication in general did not impair visual acuity (which was reduced in subjects with schizophrenia), phenothiazines in particular were shown to impair near (but not far) acuity through their effect on ciliary muscle accommodation responses (Viertio et al., 2007) , which is most relevant to reading and performing laboratory visual processing tasks. A recent study found impaired contrast sensitivity for both chromatic and achromatic stimuli in schizophrenia, with some evidence for more normal chromatic contrast sensitivity in unmedicated patients (Cadenhead et al., 2013) . Similarly, in an earlier study, in a mixed group of psychiatric patients that included many with schizophrenia, administration of antipsychotic mediation led to a global decrease in contrast sensitivity compared to controls (Bulens et al., 1987) . This was later replicated in a study demonstrating that schizophrenia patients on typical antipsychotic medications demonstrated poorer contrast sensitivity compared to both healthy controls and patients on atypical medications (Chen et al., 2003) . In some cases, these decreases in contrast sensitivity are dose-dependent (Keri et al., 2002) . Some studies of schizophrenia patients, however, have found that administration of antipsychotic medications decreases contrast sensitivity for medium and high spatial frequencies (Harris et al., 1990; Keri et al., 2002) , and increases it at low spatial frequencies (Harris et al., 1990) . Further evidence suggests that the combination of antipsychotic and antidepressant medication [a combination frequently prescribed due to high rates of depression in schizophrenia (Siris, 2000) ] is especially detrimental to contrast sensitivity (Sheremata and Chen, 2004) . It should be noted here that antipsychotic medications can interfere with vision in ways other than by reducing retinal DA, as instances of toxic maculopathy (Lee and Fern, 2004) and increased risk for cataract (McCarty et al., 1999) have been reported. However, these are far less likely to occur than the DA-depleting effects. Finally, in over half of a group of previously untreated schizophrenia patients, VEP latency increased after initiation of antipsychotic medication (Bodis-Wollner et al., 1982) .
One consequence of retinal DA receptor blockade is less input to retinal ganglion cells, which has been proposed as a mechanism of ganglion cell atrophy in Parkinson's Disease (Tian et al., 2011) . This raises the intriguing possibility that the RNFL abnormalities reviewed in the section above may be secondary to antipsychotic (and perhaps other) medication use.
Effects of excess retinal dopamine on vision
Evidence from single-photon emission computed tomography (SPECT) and positron emission tomography (PET) studies supports the traditionally held view that the acute psychotic phase of schizophrenia is characterized by hyperdopaminergia (e.g., an exaggerated response of DA neurons), whereas functioning of the DA system approaches normal levels in periods of symptom remission (Kegeles et al., 2010; Laruelle et al., 1999) . Therefore, changes in vision during acute psychotic episodes should be expected to be the opposite of those found with antipsychotic medication administration. Some evidence suggests that this is so. For example, in studies with healthy adult volunteers, L-DOPA administration improved contrast sensitivity at medium to high spatial frequencies, and decreased it at lower frequencies (Domenici et al., 1985) , and apomorphine also reduced contrast sensitivity at low frequencies in a dose-dependent fashion (Blin et al., 1991) . These effects were shown not to be a function of attention span or pupil diameter, suggesting a dopaminergic effect (Blin et al., 1991) . Similar findings were demonstrated in unmedicated schizophrenia patients, who demonstrated higher contrast sensitivity compared to healthy controls (Chen et al., 2003) . A more complex pattern of results was reported in a recent study of previously untreated first episode schizophrenia patients (Kelemen et al., 2013) . This group demonstrated greater sensitivity than controls to low, but not medium, spatial frequencies, prior to antipsychotic treatment. After initiation of treatment, this superiority disappeared, due to a reduction in sensitivity to low spatial frequencies in the schizophrenia group (i.e., not due to changes in the control group) during the treatment period. Moreover, the normalization (reduction) in LSF processing after treatment occurred in conjunction with a reduction in self-reported anomalous visual experiences. Importantly, these visual effects were independent of GABA levels in the visual cortex, which affect visual processing (Rokem et al., 2011; Yoon et al., 2010) but were unaffected by this treatment, suggesting their possible retinal origin.
Can the findings of increased LSF processing in untreated first episode patients, with a decrease after treatment (Kelemen et al., 2013) , be reconciled with the findings of an increase in LSF processing (and decreases in medium and high spatial frequency processing) after treatment in chronic schizophrenia patients (Harris et al., 1990 )? This apparent paradox may reflect important differences between the groups: while the first episode patients were characterized by a hyperdopaminergic state prior to treatment, the chronic patients had many years of treatment, were clinically stable and living in the community, and were therefore presumably not in a hyperdopaminergic state when they were switched to an injectable medication (after which, the second testing was done at the point where blood levels of the medication peaked). It is therefore possible that the results with first episode cases reflect movement from hyperdopaminergic to normal levels, whereas the results with chronic cases reflect movement from normal levels towards hypodopaminergia, similar to what is observed in studies of Parkinson's Disease (Bodis-Wollner and Tagliati, 1993) . Even so, the increase in LSF processing after injectable medication in chronic patients is curious, and may be a spurious result, given the small sample size (n = 8), the unclear diagnostic criteria used, and the fact that an increase in LSF processing after treatment was not reported in other studies. Still, the decrease in medium-high spatial frequency processing after treatment in these patients is consistent with effects observed in Parkinson's disease.
As noted above, excessive retinal DA can be expected to cause effects such as increased brightness and heightened intensity of color. Each of these has been reported (in clinical reports) in first episode schizophrenia (Chapman, 1966 ), along with a high level of visual distortions (Bunney et al., 1999; Klosterkotter et al., 2001) , and, as predicted, all of these phenomena decrease after initiation of antipsychotic medications (Kelemen et al., 2013) . In short, available, albeit limited, evidence suggests that hyperdopaminergia as found in schizophrenia is associated with excessive LSF processing, and this is consistent with other evidence of exaggerated magnocellular responsivity, and subjective changes in vision early in the illness (Keri and Benedek, 2007 ) and prior to long-term antipsychotic treatment.
Other neurotransmitters and retinal function
Glutamate is the major neurotransmitter in the vertebrate retina (de Souza et al., 2012) , is the only output neurotransmitter of the photoreceptors (Copenhagen and Jahr, 1989) , and is also released by bipolar and ganglion cells (Massey and Miller, 1990 ) (i.e., cells providing the feedforward sweep of information within and out of the retina). Moreover, glutamate output from photoreceptors is gated by the NMDA-type of glutamate receptor (Copenhagen and Jahr, 1989) . This is potentially relevant to vision in schizophrenia since: 1) various lines of evidence converge in indicating that schizophrenia is characterized by NMDA dysregulation and NMDA receptor hypoactivity, leading to increased glutamate release, and this evidence forms the basis of a leading theory of the etiology of the condition (Kantrowitz and Javitt, 2010a, b; Moghaddam and Javitt, 2012; Olney and Farber, 1995) ; 2) NMDA dysregulation is known to cause increased DA release (Javitt, 2007) , and to produce visual distortions, hallucinations, and performance on psychophysical tests of vision that resemble those found in schizophrenia (Phillips and Silverstein, 2003; Uhlhaas et al., 2007) ; 3) NMDA antagonists such as ketamine can cause pathological changes in the retina, including retinal hypoxia and cell death (Antal, 1979) , and can cause reductions in the early (sensory) visual P1 evoked potential (Lalonde et al., 2006) , which is also found in schizophrenia where it is related to level of positive symptoms (Gonzalez-Hernandez et al., 2014); and 4) many schizophrenia patients have diabetes, in many cases due to antipsychotic medication-related metabolic syndrome and weight gain, and diabetes is associated with increased retinal glutamate and retinopathy (Kowluru et al., 2001 ). To date, it has not been established that changes in glutamate function exist in the retina of people with schizophrenia (and therefore that any such changes contribute to visual functioning in people with schizophrenia). However, given the evidence noted here, we believe this is as fruitful an area to explore as that of retinal DA changes and vision in schizophrenia. One question that is particularly relevant is whether the glutamatergic input to, or from, two types of retinal cells in particular, midget and parasol cells, is altered. While the functional properties of these cell types continue to be topics of study, it is generally agreed that midget bipolar and ganglion cells have small receptive fields, are involved in color processing, and project into the LGN parvocellular pathway (Kolb, 1995; Kolb and Marshak, 2003) . In contrast, parasol ganglion cells, which receive input from DB2 and DB3 type bipolar cells (Jacoby et al., 2000) , have large receptive fields, project to the LGN magnocellular pathway, and play a role in contrast sensitivity (Crook et al., 2014) . The latter has been found to be variously underactive or overactive in schizophrenia, depending on the task, and phase of illness (Butler et al., 2001; Javitt, 2009; Kelemen et al., 2013; McClure, 2001; Schechter et al., 2003) , but retinal contributions to these effects have yet to be described.
Two other prevalent neurotransmitters in the mammalian retina are glycine and GABA (Brandstatter et al., 1998) . These neurotransmitters are involved in the inhibitory connections at horizontal and amacrine cells, which modulate the output of photoreceptor and bipolar cells. Studies of retinal connectomics have revealed multiple modes of inhibitory input for both GABA and glycine (Robert et al., 2014) . Studies of schizophrenia have also noted abnormalities in these neurotransmitter systems (Ohnuma et al., 2008; Stan and Lewis, 2012; Yamamori et al., 2014) . To date, however, the issue of contributions of retinal levels of these neurotransmitters to visual processing disturbances in schizophrenia has not been explored.
Electroretinographic changes in schizophrenia
Several studies indicate abnormal a-or b-wave activity in the ERG in schizophrenia (Lavoie et al., 2014b) . The a-wave (late receptor potential) reflects activity in the photoreceptors, whereas the b-wave primarily reflects activity in bipolar and Müller cells (other waveforms exist as well, but, with one exception, see below, these have not been studied in schizophrenia). Depending on the type of stimulation and background illumination used, these waveforms can reflect varying degrees of rod vs. cone function. All published studies to date have used the flash ERG method (pattern ERG and multifocal ERG are also commonly used in ophthalmology). The initial study of this issue (Marmor et al., 1988) focused on oscillatory potentials (fluctuations in the rise of the b-wave) which are thought to reflect output of DA-containing amacrine cells. This study found normal waveforms, but it may have been underpowered (only 12 patients and 9 controls were studied), no statistical tests were reported, and all patients were medication withdrawn, suggesting a possible self-section bias towards less severely ill patients. A later, also small, study of schizophrenia patients with healthy eyes demonstrated cone a-wave and rod a-and b-wave amplitude reductions, with these findings being unrelated to medication dose (Warner et al., 1999) . Reduced a-wave amplitude was confirmed in a later study, but the effect was only found after hospitalization for an acute psychotic episode; after 8 weeks of treatment, ERG indices were normal, suggesting a state effect. ERG data were normal at both time points in a group of bipolar disorder patients (Balogh et al., 2008) . In the largest study to date, comparing 105 schizophrenia patients to 150 controls, patients differed significantly from controls on cone a-wave amplitude, mixed rod-cone b-wave amplitude and pure rod b-wave amplitude, with trends noted for other amplitude and latency variables (Hebert et al., 2015) . As with earlier studies, the findings were not related to level of medication, or tobacco, use. Finally, reduced rod b-wave amplitude and longer latencies were found in a group of unaffected offspring of parents with schizophrenia or bipolar disorder (there was no effect of parental diagnosis; Hébert et al., 2010) . Cone activity was normal, as was rod a-wave activity in this sample. Although much more data are need on this issue, existing data suggest abnormal retinal function at the level of photoreceptors during acute psychosis, and at the level of the bipolar-Müller cells in patients and high-risk subjects regardless of clinical state. As with OCT data, it is not clear whether these findings are causes of later visual processing impairments, or whether they reflect parallel disturbances in brain function, or both. One proposed mechanism of ERG abnormalities in schizophrenia is reduced omega-3 fatty acid concentration in retinal tissue, where it is normally very dense. This hypothesis is consistent with data on reduced omega-3 fatty acid levels in the brain in schizophrenia (Ohara, 2007) , with the therapeutic effects of omega-3 supplementation in schizophrenia (McNamara and Strawn, 2013) , and with known effects of fatty acid depletion on retinal function and ERG indices (Neuringer et al., 1986) . However, it is also hypothesized that ERG abnormalities reflect DA and serotonin changes, paralleling similar changes in the brain (Lavoie et al., 2014a) .
Visual acuity changes and their implications in schizophrenia
Poor performance on tests of visual perception (and other cognitive tasks involving visual stimuli) is assumed to reflect the process under investigation, and little attention has been paid to the possibility that reduced visual acuity could play a role. We believe this needs to change, given past findings of poorer visual acuity in schizophrenia, but not other psychotic disorder, patients (including that caused by medication) (Viertio et al., 2007) , with one study reporting that close to 70% of a schizophrenia patient sample had untreated visual acuity problems (Smith et al., 1997) [although some studies reported lower rates [e.g., 26% (Souza et al., 2008) ] this is still excessive]. While the role of acuity changes in performance on perceptual (and other) tasks in driving between group differences in studies of schizophrenia is generally not known, recent evidence suggests a role. For example, in a study that matched patients and controls on visual acuity, no differences were found in low and high spatial frequency processing conditions (in contrast to many past studies), and, in the sample as a whole, reduced high spatial frequency processing was related to lower acuity (Silverstein et al., 2014) . This suggests that at least some prior findings of group differences in spatial frequency processing, or where detail processing is critical to task performance, or where visual stimuli are degraded (Knott et al., 1999; Nuechterlein et al., 1986) , or even in reading (Revheim et al., 2006a (Revheim et al., , 2014 , could be due, at least in part, to betweengroup acuity differences (even when these are within the normal range, see below). It also raises the possibility that the observed bias towards LSF processing in some studies (Laprevote et al., 2010 (Laprevote et al., , 2013 may be due to an illness-related bias that has developed to preferentially process LSFs, even when HSF processing is adequate for the task. But, even within the range of normal vision (i.e., 20/32 or better), acuity makes a difference. Another recent study demonstrated that, among healthy controls, people with 20/16 vision performed significantly better than subjects with 20/20 vision on tests of contour integration and collinear facilitation (Keane et al., 2014b) , two measures on which schizophrenia patients have performed abnormally in multiple studies (Keri et al., 2005a (Keri et al., , 2005b (Keri et al., , 2009 Silverstein et al., 2000 Silverstein et al., , 2012a . This was recently replicated in a separate sample of schizophrenia patients and controls (Keane et al., 2014c) . The implication of this is that demonstrating that all subjects (patients and controls) have "normal or corrected to normal vision" is not enough, especially since schizophrenia patients, with their poorer health care (Marder et al., 2004) including less frequent eye examinations (Viertio et al., 2007) [including in patients with diabetes (De Hert et al., 2011) ], can be assumed to have poorer acuity than controls even when it is roughly within the normal range.
Importantly, acuity differences may precede diagnosis. For example, poorer visual acuity, but not other sensory impairments, at 4 years old predicted a diagnosis of schizophrenia, but not other psychiatric diagnoses, in adulthood (Schubert et al., 2005) .
Finally, since many antipsychotic medications have anticholinergic effects, and these are known to include dilated pupils and blurred vision (Lieberman, 2004) , and similar effects are caused by medications used to treat movement side effects in schizophrenia (e.g., benztropine), medication use may compound visual acuity impairments in people with schizophrenia.
In short, future studies of perceptual impairment in schizophrenia, or of other functions that involve processing visual stimuli should describe the extent to which reduced visual acuity contributes to abnormal performance.
Ocular abnormalities and their implications for schizophrenia
In addition to acuity differences, other ocular changes related to schizophrenia, lack of good health care in people with this condition, and/or to its treatment can affect performance on visual processing tasks. For example, Smith et al. (1997) reported that 82.6% of a sample of schizophrenia patients had lens opacities, cataracts, or corneal pigmentation. This study also found that cataracts were more common in patients on first-generation (40%), compared to second-generation antipsychotic medications (18%).
Another condition more common in schizophrenia than the general population is strabismus (Yoshitsugu et al., 2006) , or differential alignment of the eyes. Elevated rates of strabismus have also been found in children who later develop schizophrenia (Schiffman et al., 2006) . This can result in amblyopia, and depth perception difficulties, and people with schizophrenia have shown poor performance on visual tasks such as contour integration that resembles that of people with amblyopia (Hess et al., 1997; Kiorpes, 2006; Kovács et al., 2000; Silverstein et al., 2000 Silverstein et al., , 2012a , as well as problems with depth perception (Schechter et al., 2006) .
Whether resulting from illness-related processes, general neurological vulnerabilities, antipsychotic medication, or a lack of adequate health care, these conditions can affect visual processing. However, at least some of these problems are likely to be primary, because children who later developed schizophrenia in adulthood have been shown to have poorer ocular alignment (i.e., higher strabismus scale scores) than children who did not develop schizophrenia (Schiffman et al., 2006) . Whether primary or secondary, however, studies of perception in schizophrenia typically do not screen for ocular problems, and thus their contribution to past findings is not known.
Does congenital blindness exert a protective effect against schizophrenia?
Since 1950 (Chevigny and Braverman, 1950) , it has been proposed multiple times that, since there have been no reports of people with schizophrenia who were born blind, congenital blindness may confer a complete or partially protective effect against schizophrenia. Two recent reviews have summarized this literature, and explored mechanisms whereby this effect may operate (Landgraf and Osterheider, 2013; Silverstein et al., 2012b) . These include: 1) abnormal visual input that precedes, and characterizes, schizophrenia is eliminated; 2) many of the cognitive functions that are impaired in schizophrenia are enhanced among the congenitally blind (see Table 1 ), suggesting that the cortical reorganization following birth results in a brain that is essentially protected against the development of this condition; and 3) congenital blindness involves reduced flexibility in language and in dynamic representation of the body, and these reductions may protect against thought disorder and alterations in experience of the self, two additional aspects of schizophrenia. Importantly: 1) these effects are much reduced if onset of blindness is after the first few months of life; 2) other forms of congenital sensory loss do not protect against schizophrenia (and some are associated with increased risk); 3) congenital blindness does not protect against other psychiatric disorders suggesting that there is a special link between schizophrenia and visual processing; and 4) past findings of an inverse relationship between the conditions are not due to their relatively low base rates . However, much remains to be learned about this inverse relationship, which parallels, but appears to be stronger than, the one between schizophrenia and rheumatoid arthritis (Gorwood et al., 2004; Mors et al., 1999) . For example, there are multiple ways that blindness can occur, with varying contributions of the eyes, subcortical structures (e.g., LGN), and visual cortex, and the extent to which these contributions may vary in their association with schizophrenia is unclear.
Conclusions
The evidence reviewed above suggests two major conclusions. One is that there are multiple structural and physiological disturbances of the eye associated with schizophrenia, all of which could contribute to the visual processing impairments, and altered visual experiences found in the disorder. These include retinal venule widening (possibly secondary to tissue loss), ganglion cell axon (and possibly cell body) loss, dopaminergic abnormalities in photoreceptors, reduced GABAand glycine-related lateral inhibition, various maculopathies and retinopathies, cataracts, poor visual acuity, and strabismus. Some of these are likely to be related to the illness itself, whereas others may be due to medication use or comorbid conditions such as diabetes (i.e., diabetic retinopathy). In some cases, it has already been shown that variability in these phenomena (e.g., visual acuity) affects performance on visual processing tasks on which schizophrenia patients have demonstrated impairment. A second conclusion suggested by the evidence is that aspects of retinal structure and function can serve as biomarkers of brain pathology, and disease progression, in schizophrenia. The strongest evidence for this to date involves the markers of widened retinal venules, thinning of the RNFL, and abnormal ERG (a and b) waveforms. This and other evidence suggests that the fast and accurate indices provided by ERG, digital retinal imaging, OCT, and even color vision assessment may be useful surrogate measures of global cognitive functioning and specific cognitive impairments (e.g., cognitive control), as well as of disease progression over time, as is the case in other CNS disorders such as Parkinson's disease and MS. Regarding color perception in particular, more definitive studies in medicated patients are needed, as are studies investigating the possibility of heightened color sensitivity in unmedicated first-episode patients (especially in those reporting color hue and intensity distortions), to determine whether there is excessive activity at cone D2 receptors. To our knowledge, such studies have not yet been conducted.
The goal of this review was to highlight potential contributors to the visual processing abnormalities of schizophrenia and high-risk states that are local to the retina or other structures of the eye. The main weakness of the argument is the relatively small amount of direct evidence of these effects to date. However, we believe that findings from other disorders such as Parkinson's disease and MS, along with the known problems in acuity and eye disease in schizophrenia, and the relative consistency in the albeit small number of OCT and ERG studies of schizophrenia, provide sufficiently compelling evidence to suggest the need for further investigation.
Finally, because post-ocular structures, such as the LGN and visual cortex, also rely on DA, glutamate, GABA and other neurotransmitters, it will be a challenge to distinguish which effects are local to the retina, as opposed to subcortical or cortical. Some aspects of visual impairment in schizophrenia (e.g., involving orientation discrimination) clearly involve cortical contributions due to known properties of visual cortex (e.g., orientation specific columns). Others, such as reduced susceptibility to certain visual illusions, appear to involve reduced influences of stored knowledge on perception, reflecting altered connectivity between frontal and parietal regions and higher level visual regions (Dima et al., 2009; Keane et al., 2013) . In addition, since, for example, there are~20 types of retinal ganglion cells, which cover the retina in a mosaic-type pattern, and whose output is integrated in the LGN, with each contributing a different aspect of information about the visual stimulus (Roska and Meister, 2014) , some visual processing impairments may reflect abnormal coordination of ganglion cell outputs in the LGN. This is particularly relevant given that there are abnormalities in coordinating neural activity that are found throughout the cortex, and that characterize intermediate and higher-level visual processing and cognitive impairments (Phillips and Silverstein, 2003) . However, even with functions such as coordination of ganglion cell output, orientation discrimination, and perceptual organization, as well as higher-level processes such as illusion perception, visual memory, and visual learning, degraded retinal input could serve as a rate-limiting factor. In contrast, with lower level visual processes such as brightness and motion representation, contrast sensitivity, spatial frequency processing, and color processing, retinal contributions have long been acknowledged. Therefore, we believe that a more comprehensive understanding of the nature of the full range of visual processing and visual cognition impairments in schizophrenia requires that retinal contributions be more precisely determined.
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